|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US6852690B1
(en)
|
1995-08-22 |
2005-02-08 |
Amylin Pharmaceuticals, Inc. |
Method and composition for enhanced parenteral nutrition
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
US6380357B2
(en)
|
1997-12-16 |
2002-04-30 |
Eli Lilly And Company |
Glucagon-like peptide-1 crystals
|
|
US6998387B1
(en)
*
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
US7223727B2
(en)
|
1998-04-09 |
2007-05-29 |
Serono Genetics Institute S.A. |
GSSP4 polynucleotides and polypeptides and uses thereof
|
|
US6720407B1
(en)
*
|
1998-08-28 |
2004-04-13 |
Eli Lilly And Company |
Method for administering insulinotropic peptides
|
|
US6927214B1
(en)
|
1999-01-15 |
2005-08-09 |
Novo Nordisk A/S |
Non-peptide GLP-1 agonists
|
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
|
DK1808438T3
(da)
|
1999-06-29 |
2014-10-27 |
Mannkind Corp |
Rensning og stabilisering af peptid og proteiner i lægemidler
|
|
WO2001032200A1
(en)
*
|
1999-11-03 |
2001-05-10 |
Novo Nordisk A/S |
Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety
|
|
CA2405550A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP1283058A4
(en)
*
|
2000-05-16 |
2004-06-23 |
Sanwa Kagaku Kenkyusho Co |
AGENTS FOR PREVENTING OR IMPROVING INSULIN RESISTANCE AND / OR OBESITY
|
|
ATE405323T1
(de)
*
|
2001-02-09 |
2008-09-15 |
Serono Genetics Inst Sa |
Gssp4-polynukleotide und -polypeptide sowie deren verwendung
|
|
NZ532427A
(en)
|
2001-09-24 |
2008-07-31 |
Imp Innovations Ltd |
Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
|
|
AU2002364586A1
(en)
|
2001-12-21 |
2003-07-30 |
Delta Biotechnology Limited |
Albumin fusion proteins
|
|
CA2484556A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
JP4417113B2
(ja)
|
2002-02-20 |
2010-02-17 |
エミスフェアー・テクノロジーズ・インク |
Ｇｌｐ−１分子の投与方法
|
|
AU2003220125B2
(en)
|
2002-03-20 |
2006-06-15 |
Mannkind Corporation |
Inhalation apparatus
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
CA2513213C
(en)
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
WO2005056036A2
(en)
|
2003-12-09 |
2005-06-23 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
SI1729795T1
(sl)
|
2004-02-09 |
2016-04-29 |
Human Genome Sciences, Inc. |
Albuminski fuzijski proteini
|
|
PT1745078E
(pt)
|
2004-04-23 |
2009-09-17 |
Conjuchem Biotechnologies Inc |
Método para a purificação de conjugados de albumina
|
|
US8410047B2
(en)
|
2004-06-11 |
2013-04-02 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
|
PL1786784T3
(pl)
|
2004-08-20 |
2011-04-29 |
Mannkind Corp |
Kataliza syntezy diketopiperazyn
|
|
EP2314298B1
(en)
|
2004-08-23 |
2015-05-27 |
MannKind Corporation |
Microparticles comprising diketopiperazine salts for drug delivery
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
EP1904525A4
(en)
|
2005-06-30 |
2009-10-21 |
Ipsen Pharma |
GLP-1 PHARMACEUTICAL COMPOSITIONS
|
|
AU2006290870B2
(en)
|
2005-09-14 |
2013-02-28 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
|
|
ES2397289T3
(es)
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
|
WO2007053946A1
(en)
|
2005-11-09 |
2007-05-18 |
Conjuchem Biotechnologies Inc. |
Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
|
|
EP2364735A3
(en)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Branched PEG conjugates of GLP-1
|
|
DK1986679T3
(da)
|
2006-02-22 |
2017-11-20 |
Mannkind Corp |
Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
EP1854455B1
(en)
|
2006-05-10 |
2009-10-07 |
Biocompatibles UK Limited |
Spherical microcapsules comprising GLP-1 peptides, their production and use
|
|
ES2371495T3
(es)
*
|
2006-07-24 |
2012-01-03 |
Biorexis Pharmaceutical Corporation |
Proteínas de fusión de exendina.
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
ES2550363T3
(es)
*
|
2007-09-05 |
2015-11-06 |
Novo Nordisk A/S |
Derivados truncados de GLP-1 y su uso terapéutico
|
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
AU2008316634B2
(en)
*
|
2007-10-24 |
2014-02-27 |
Mannkind Corporation |
Method of preventing adverse effects by GLP-1
|
|
WO2009055742A2
(en)
*
|
2007-10-24 |
2009-04-30 |
Mannkind Corporation |
Delivery of active agents
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
CN103252007B
(zh)
|
2008-06-13 |
2016-06-22 |
曼金德公司 |
干粉吸入器和用于药物输送的系统
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
JP5479465B2
(ja)
|
2008-06-20 |
2014-04-23 |
マンカインド コーポレイション |
吸入努力をリアルタイムにプロファイルする対話式機器および方法
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
TWI614024B
(zh)
|
2008-08-11 |
2018-02-11 |
曼凱公司 |
超快起作用胰島素之用途
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
|
EP2216042A1
(en)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
GLP-1 analogues pharmaceutical compositions
|
|
EP2676695A3
(en)
|
2009-03-11 |
2017-03-01 |
MannKind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
|
KR101875969B1
(ko)
|
2009-06-12 |
2018-07-06 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
WO2011056889A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
|
PH12012501037A1
(en)
|
2009-11-27 |
2013-01-14 |
Boehringer Ingelheim Int |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
|
CA2797310C
(en)
|
2010-05-05 |
2020-03-31 |
Boehringer Ingelheim International Gmbh |
Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
|
|
RU2531455C2
(ru)
|
2010-06-21 |
2014-10-20 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
|
MX2013000250A
(es)
|
2010-07-02 |
2013-10-28 |
Angiochem Inc |
Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
RU2600440C3
(ru)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
|
|
CN105667994B
(zh)
|
2011-04-01 |
2018-04-06 |
曼金德公司 |
用于药物药盒的泡罩包装
|
|
CA2832811A1
(en)
|
2011-04-12 |
2012-10-18 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
|
WO2013063160A1
(en)
|
2011-10-24 |
2013-05-02 |
Mannkind Corporation |
Methods and compositions for treating pain
|
|
US20130172244A1
(en)
*
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
ES2715308T3
(es)
|
2012-03-22 |
2019-06-03 |
Novo Nordisk As |
Composiciones que comprenden un agente de suministro y su preparación
|
|
US10933120B2
(en)
|
2012-03-22 |
2021-03-02 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
|
EP4151218A1
(en)
|
2012-05-14 |
2023-03-22 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
|
SG11201500218VA
(en)
|
2012-07-12 |
2015-03-30 |
Mannkind Corp |
Dry powder drug delivery systems and methods
|
|
EP2911690A1
(en)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalable influenza vaccine compositions and methods
|
|
EP2970149B1
(en)
|
2013-03-15 |
2019-08-21 |
MannKind Corporation |
Microcrystalline diketopiperazine compositions and methods
|
|
AU2014261336B2
(en)
|
2013-05-02 |
2019-02-28 |
Novo Nordisk A/S |
Oral dosing of GLP-1 compounds
|
|
HUE057361T2
(hu)
|
2013-05-28 |
2022-05-28 |
Takeda Pharmaceuticals Co |
Peptid vegyület
|
|
CN105451716A
(zh)
|
2013-07-18 |
2016-03-30 |
曼金德公司 |
热稳定性干粉药物组合物和方法
|
|
WO2015021064A1
(en)
|
2013-08-05 |
2015-02-12 |
Mannkind Corporation |
Insufflation apparatus and methods
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
|
WO2017204219A1
(ja)
|
2016-05-24 |
2017-11-30 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
BR112020014624A2
(pt)
|
2018-02-02 |
2020-12-08 |
Novo Nordisk A/S |
Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
|
|
CN110237239A
(zh)
*
|
2018-03-09 |
2019-09-17 |
上海仁会生物制药股份有限公司 |
用于治疗肥胖和体重管理的glp-1组合物
|